Incretin-based Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The incretin based drugs market size is expected to grow from USD 34.78 billion in 2025 to USD 37.10 billion in 2026 and is forecast to reach USD 51.19 billion by 2031 at 6.67% CAGR over 2026-2031. This report is Segmented by Drug Type (GLP-1 Receptor Agonists, and More), Route of Administration (Injectable, Oral), Distribution Channel (Hospital Pharmacies, and More), Primary Indication (Type 2 Diabetes, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Incretin-based Drugs Market Trends and Insights

GLP-1 Blockbuster Launches Outpacing Supply

Severe manufacturing bottlenecks persisted in 2024, leaving patients waiting months for prescriptions and prompting premium pricing that protected revenue despite volume gaps. Eli Lilly earmarked USD 23 billion for new peptide facilities across three continents to relieve the deficit, yet analysts expect tight supply until mid-2026. Pharmacies in major U.S. cities introduced rationing lists, while European wholesalers prioritized cardiovascular-risk patients. The dislocation spurred parallel import and compounding channels that challenge quality oversight. As capacity comes online, the incretin based drugs market will likely see a burst of deferred demand, lifting unit sales faster than price cuts can dilute revenue.

Rapid Obesity-Centric Label Expansions

Regulatory agencies accelerated weight-management approvals after trials confirmed up to 22.5% body-weight reduction and 93% diabetes-progression risk decline with tirzepatide. FDA and EMA green-lit cardiovascular benefit claims for GLP-1s, widening prescribing beyond endocrinology to cardiology and primary care. The broader labeling creates multiple reimbursement pathways and encourages earlier intervention, especially in high-risk prediabetes populations. Payors in the United States now reimburse obesity use for patients with heart failure or chronic kidney disease, a decision mirrored by private insurers in Germany and Australia. As label scope grows, routine polysymptomatic screening is expected to lift diagnosis rates, feeding additional volume to the incretin based drugs market.

Limited Reimbursement Outside US & Select EU Payors

Brazil’s ANVISA approved tirzepatide yet monthly therapy costs between BRL 1,883 and BRL 4,007 (USD 376-800) put it beyond reach of average wage earners. Similar affordability gaps exist in India, Indonesia and South Africa where public payors restrict coverage to severe cases or require prior failure of cheaper oral agents. The reimbursement divide creates a two-tier adoption curve that slows volume growth outside premium economies, capping upside for the incretin based drugs market until flexible contracting or local manufacturing narrows cost gaps.

Other drivers and restraints analyzed in the detailed report include:

• Surge in Self-Pay Channels & Digital DTC Prescribing
• Oral Small-Molecule GLP-1 Pipeline Improving Adherence
• Dual/Triple Incretin Agonists Showing >20% Extra Weight Loss
• Persistent Global Supply Shortages Through 2026
• Safety-Signal Overhangs (Thyroid C-Cell, GI Events)

Segment Analysis

GLP-1 receptor agonists generated 61.78% of the incretin based drugs market size in 2025 on the strength of broad clinical evidence and payer familiarity. Dual/triple agonists, however, outpace all classes at a 6.85% CAGR through 2031 as superior 20%-25% weight-loss efficacy drives physician switching. Early real-world data show tirzepatide cutting HbA1c by 2.3 points in uncontrolled diabetics versus 1.7 points for liraglutide. DPP-4 inhibitors decline in relevance yet retain footing in fixed-dose combinations aimed at cost-sensitive segments. Pipeline entrants such as survodutide and cotadutide showcase triple-pathway modulation, positioning the incretin based drugs market for continual therapeutic breakthroughs.

The dual-mechanism surge reshapes competitive moats; innovators secure new composition-of-matter patents that defer biosimilar threats and sustain premium positioning. As clinical guidelines migrate toward weight-first management, single-hormone GLP-1s risk price erosion and must pivot to once-weekly depot or oral formats to defend share. Consequently, the incretin based drugs market sees an arms race of mechanistic complexity, with multi-agonists establishing a new standard for metabolic disease control.

Injectables dominated the incretin based drugs market with 77.85% share in 2025 due to reliable bioavailability and clinician comfort. Yet oral formats post a 7.01% CAGR as permeability enhancers and stabilizing excipients offset digestive degradation, delivering efficacy on par with subcutaneous routes. Patient surveys indicate 68% preference for pills over pens when cost parity exists, highlighting latent demand. Primary-care physicians report shorter education sessions and higher refill persistence among oral users, translating into durable revenue accrual.

Scaling oral GLP-1 manufacturing requires separate tableting suites and stringent moisture controls, raising capex. However, those investments enable differentiated brand stories that reduce rebate exposure in the crowded injectable category. Over the forecast, oral penetration should lift overall adherence, enlarging the incretin based drugs market and lowering late-stage complication costs for health systems.

Complete Report Scope:

• By Drug Type
  • GLP-1 Receptor Agonists
  • Dual / Triple Incretin Agonists
  • DPP-4 Inhibitors
  • Others / Pipeline Classes
• By Route of Administration
  • Injectable
  • Oral
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online / Specialty Pharmacies
• By Primary Indication
  • Type 2 Diabetes
  • Obesity / Weight Management
  • Cardiometabolic Co-morbidities
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 43.10% of the incretin based drugs market in 2025, supported by employer-based insurance that absorbs USD 1,000-plus monthly list prices and by active telehealth uptake that accelerates initiation. FDA fast-track designations for cardiometabolic uses keep the approval pipeline robust, and bipartisan legislative interest in obesity care hints at future Medicare coverage expansion. Canada mirrors U.S. clinical enthusiasm but negotiates lower net pricing through centralized procurement, moderating revenue per patient.

Europe delivers steady but heterogeneous demand. Germany and the United Kingdom reimburse GLP-1s for BMI ≥30 kg/m² plus comorbidities, while Italy and Spain impose stricter BMI triggers, dampening volume. Health technology assessment agencies increasingly factor cardiovascular benefits into cost-effectiveness models, a shift likely to unlock broader access by 2027. Regional purchasing alliances may, however, pressure list prices, nudging manufacturers toward outcomes-based contracts to protect margin within the incretin based drugs market.

Asia-Pacific is the fastest-growing region at 7.98% CAGR, driven by rapid urbanization and rising obesity prevalence. China’s cost-utility studies validate tirzepatide’s economic merit despite premium positioning, paving the way for volume-based procurement frameworks. Japan authorized obesity labeling in 2025, creating new reimbursement pathways, while Australia struggles with restricted formulary budgets, relying on patient copay programs. India straddles producer-consumer roles: domestic peptide output lowers COGS, yet public reimbursement remains limited, fostering a robust private-pay segment that nevertheless enlarges the incretin based drugs industry footprint.

List of Companies Covered in this Report:

• Novo Nordisk
• Eli Lilly and Company
• Sanofi
• Merck
• AstraZeneca
• Boehringer Ingelheim
• Takeda Pharmaceuticals
• LG Chem
• Amgen
• Viking Therapeutics
• Johnson & Johnson
• Pfizer
• Dong-A ST
• Oramed Pharma
• Terns Pharmaceuticals
• Chia Tai Tianqing
• Hanmi Pharma
• AstraZeneca /Daiichi’s Eflornithine JV
• Biocon
• Amneal Pharma
• Teva Pharma
• Lupin

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support